Candidiasis can be present as a cutaneous, mucosal or deep-seated organ infection, which
is caused by more than 20 types of Candida sp., with C. albicans being the most common …

Invasive Candida infections remain an important cause of morbidity and mortality, especially
in hospitalized and immunocompromised or critically ill patients. A limited number of …

The high clinical mortality and economic burden posed by invasive fungal infections (IFIs),
along with significant agricultural crop loss caused by various fungal species, has resulted in …

Candida albicans and the emerging non-albicans Candida spp. have significant clinical
relevance among many patient populations. Current treatment guidelines include …

Within the limited antifungal armamentarium, the azole antifungals are the most frequent
class used to treat Candida infections. Azole antifungals such as fluconazole are often …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Background. Fluconazole (FLC) resistance is common in C. glabrata and echinocandins are
often used as first-line therapy. Resistance to echinocandin therapy has been associated …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …

Despite improvement of antifungal therapies over the last 30 years, the phenomenon of
antifungal resistance is still of major concern in clinical practice. In the last 10 years the …